key: cord-0800442-4bjibk8j
authors: Chan, Daniel Kam Yin; Day, Ric
title: Precision medicine and clinical relevance in older people
date: 2021-09-27
journal: Aging Med (Milton)
DOI: 10.1002/agm2.12178
sha: 3fc4ceb819b27d500175f28e013115a3995ef204
doc_id: 800442
cord_uid: 4bjibk8j

Precision medicine and clinical relevance in older people. [Image: see text]

approach. Therefore, it is especially relevant in older patients, where comorbidities and many individual variabilities such as age, environment, and genomics are the norm.

Geriatricians in some ways already practice some basic principles similar to precision medicine. For instance, the principle of "start low and go slow" when initiating drug therapy allows for better and safer dosing. 1 However, to be more systematic in patient management, it would be beneficial to understand how this emerging field is affecting the clinical care of older people.

Firstly, the in-depth knowledge we have with pharmacodynamics and pharmacokinetics sets a good foundation for precision medicine. The variability of age, sex, renal, and hepatic function are just some vital determinants we already know to take into account when prescribing for older people. Other factors such as environmental Finally, one of the main reasons to date why geriatric medicine still lacks preciseness is that many randomized controlled trials exclude the recruitment of older people with multiple comorbidities. Therefore, while the internal validity of the trials is good, the external validity or generalization is a problem, especially to the older age group. Hence, geriatricians often have to "guestimate" the likely efficacy and do a balancing act on harm and benefit. A more accurate means would be to include older people in the drug trials but safeguard them with individualizing the doses that they would need for treatment, using the knowledge of genotyping, liquid biopsy, as well as other traditional tools such as pharmacodynamics and pharmacokinetics. Thus, results obtained from trials can be more generalizable to our older population. This a priori (instead of a posteriori) approach would mean simulation or modeling of trial conditions required beforehand.

In conclusion, the speed of the advance in medicine is enormous and precision medicine is at hand for us to use to improve the health of older people who will benefit from this approach. Geriatricians should embrace it rather than shy away from it.

We thank Annette Gross for part of the figure in the abstract that we adopted and modified and Sarah Tan for the illustration in the abstract. 

Polypharmacy and adverse drug reaction. Chan's Practical Geriatrics

Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters

Liquid biopsy enters the clinic -implementation issues and future challenges

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Precision medicine and clinical relevance in older people